In today’s challenging market, business planners and commercial management must ask themselves some key questions, such as...
Who are the winners and losers in terms of revenue growth?
Which companies have succeeded in maintaining or growing profits?
Overall R&D investment from the top 10 companies fell between 2008 and 2009 by US$421 million from US$57.54 billion to US$57.12 billion – yet some companies maintained or expanded R&D spend. Who were they?
Who are the fastest growers? 10 companies with joint 2005 sales of US$2.55 billion posted sales of $US13.06 billion in 2009. Who were they?
Which companies are cash rich or cash poor?
Pharmaceutical Company Performance Tables
The answers to thousands of key questions are in the new November 2010 edition
This essential fully-updated business reference report compares and contrasts the performance and fortunes of leading pharmaceutical companies and places them in easy-to-read tables. Importantly, in addition to rankings, the new edition of the report includes the individual results for 162 companies and up to five years of key data from the balance sheet, income statement and cash flow.
Key Facts & Benefits of this report:
Full 2009 year-end figures
Contains a wide range of detailed performance rankings for more than 160 leading pharmaceutical companies
Includes individual company results
Provides up to five years of trend data
Available in print or pdf with web access included free of charge!
Trends affecting the global industry
The challenging economic environment continues to affect health spending in many countries which has impacted the pharmaceutical industry’s commercial performance. Issues which are affecting companies’ performance, include...
The number of blockbuster drugs which have lost patent protection, and the number is set to rise over the coming years, have not been replaced by new products offering significant therapeutic advances
Those products which have been launched – increasingly in the biological area – have attracted criticism and objection from health payers due to their high cost
Many companies continue to post rising revenues and increasing profits, although for many it is against a background of cost cutting
Mergers and acquisitions, and especially technology/product acquisition, have taken an increasing role in market entry/expansion plans
Generic competition continues to erode the profits of off-patent products, although spending constraints and rising competition are creating pressure in the generic sector.
Pharmaceutical Companies Performance Tables A unique opportunity to assess companies’ financial and operating performances.
Use it for...
Partnering and licensing background
PR and Marketing
Just some of the 162 companies in the 2010 edition...